Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07231497 · ClinicalTrials.gov registry record · Phase 3
Cognitive Strategies in Early Psychosis 1
A Phase 3 study of Healthy Participants and Cognition, sponsored by University of Minnesota.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 103
- Enrollment target
- 1
- Study location
NCT07231497 is a Phase 3 study of Healthy Participants and Cognition that is actively recruiting participants, run by University of Minnesota. The registered enrollment target is 103 participants, above the 65-participant average among 119 other Healthy Participants trials with a reported enrollment target (58% higher). The trial reports 1 study location across 1 state.
The verdict
NCT07231497, a Phase 3 study of Healthy Participants and Cognition, is actively recruiting participants, sponsored by University of Minnesota.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 103 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical is to learn more about decision making in psychosis spectrum disorders, like schizophrenia. The investigators will ask people who do not have psychosis to take a single dose of modafinil and then complete some brain games on the computer that measure decision making. They hope to improve our understanding of psychosis to help people in the future. The main research questions are: Does a single dose of modafinil change how people play the brain games? Does a single dose of modafinil change brain activity? Participants will: Complete an interview and self-report questionnaires. Complete safety screening activities, like a blood draw, a urine drug test, and an alcohol breathalyzer test. Take a single dose of modafinil. Complete brain games while wearing an electroencephalography (EEG) cap, before and after taking the single dose of modafinil. EEG measures electrical activity in the brain.
Conditions Studied
Interventions
- DRUG Modafinil
Study Locations (1)
Minnesota
- University of Minnesota - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 103 participants |
| Start Date | 2025-10-31 |
| Est. Completion | 2030-04-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07231497
The ClinicalTrials.gov registry entry for NCT07231497 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 103 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 65-participant average among 119 other Healthy Participants trials with a reported enrollment target (58% higher). The listed sponsor is University of Minnesota, which has 966 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Healthy Participants appearing as the primary indexed condition, and to 1 intervention - of which Modafinil is the first listed.
NCT07231497 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT07231497 about?
NCT07231497 is a clinical study titled "Cognitive Strategies in Early Psychosis 1". The goal of this clinical is to learn more about decision making in psychosis spectrum disorders, like schizophrenia. The investigators will ask people who do not have psychosis to take a single dose of modafinil and then complete some brain games on the computer that measure decision making. They h...
What is the current status of trial NCT07231497?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 103 participants. The study started on 2025-10-31. Estimated completion is 2030-04-30.
What conditions does trial NCT07231497 study?
This clinical trial studies the following conditions: Healthy Participants, Cognition.
What interventions are being tested in trial NCT07231497?
The interventions under investigation include: Modafinil (DRUG).
Who is sponsoring clinical trial NCT07231497?
This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07231497 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy Participants
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Assess the Bioequivalence of Trastuzumab Via Different Subcutaneous Delivery Platforms in Healthy Male Participants
RECRUITING · Phase 1
-
Impact of Exogenous Ketones on Sleep and Breathing in Healthy Volunteers (K-SLEEP)
RECRUITING · Phase 1
-
Impact of Supplemental Fiber on Gut and Vascular Health Related in Obesity Phenotypes
RECRUITING · NA
-
A Study to Investigate the Concentrations of Zibotentan and Dapagliflozin in Blood When Given With and Without Food
RECRUITING · Phase 1
-
A Food Effect Study to Evaluate the Relative Bioavailability of Nalbuphine Extended-Release Tablets (NAL ER) in Healthy Participants
RECRUITING · Phase 1
-
Fructose Intestinal Gluconeogenesis
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.